• ACCELERATE DRUG DISCOVERY

  The rising cost of drug discovery has outpaced the number of new medicines reaching the market.  The pharmaceutical and biotechnology industry is re-thinking approaches deployed in the earliest stages to enhance downstream success.  VeraVec ECs have the potential to transform drug discovery by providing a more physiologically relevant environment to support in vitro assays used to understand basic mechanisms of disease and to identify safe and efficacious clinical compounds.

• BOOST THE HEMATOPOIETIC SYSTEM

  Umbilical cord blood is a rich source of stem cells that has been used in the treatment of over 80 diseases, including leukemia, lymphoma and anemia.  Using this as a model of ex vivo expansion, a supportive cellular platform of VeraVec ECs is capable of a 1200-fold expansion of total hematopoietic cells in just 12 days, including cells with the surface phenotype lineage – CD34+ CD45+ CD49f+ CD45RA-. Expanded HSPCs are competent to engraft into both primary and secondary recipients.

• REVEAL THE COMPLEXITY OF VASCULAR PHYSIOLOGY

  VeraVec ECs are resistant to the damaging effects of prolonged serum-dependence, resulting in a highly stable and proliferative EC population compared to naïve cells. Human ECs can be cultured in media that is completely absent of complex media additives without negatively affecting their viability or stability.

• ESTABLISH NOVEL In Vitro MODEL SYSTEMS

  The animal system of choice for many researchers is the mouse.  Each tissue is endowed with unique vasculature at the molecular and structural levels.  The repertoire of Angiocrine factors supplied by the endothelium is part of what defines endothelial cell heterogeneity and ultimately the biology of the tissue.  With VeraVec Mouse ECs it is now possible to study ECs from each individual vascular bed.

• ADVANCE R&D THROUGH PARTNERING

  Breakthrough therapies of tomorrow will occur only through driving deeper collaborative efforts across the healthcare spectrum.  Key to drug discovery is access to innovative, cost effective technologies that can improve the efficiency of designing more effective therapies that improve health outcomes in the clinic.  Angiocrine Bioscience offers a creative, flexible and open collaboration framework to deliver innovative scientific results.